20 – CRI Report

Research Report on Avocado Imports in China 2020-2024

admin — Wed, 02 Sep 2020 02:55:49 +0000

Avocado Imports in China

Avocado is a kind of fruit with high nutritional value, which is widely used in food, medicine and cosmetic industries.

According to CRI, the opportunity for avocado to enter the Chinese market coincides with the vigorous development of e-commerce in China. Various related sales have exposed Online shopping promotes avocado sales, so it quickly become a “famous fruit”, driving the import volume.

According to CRI, from 2014 to 2015, Peru and Chile successively obtained the access certificate for the export of avocados to China and enjoyed the preferential treatment of zero tariff, thus the avocado market has entered a period of rapid growth.

According to CRI, avocado is one of the fastest growing fruits in China. In 2010, China imported only 2 tons of avocado. By 2017, the number had increased to 32.14 kilotons, with an increase of about 16 thousand times in seven years. In 2018, China imported the largest number of avocados, reaching 43.86 kilotons, with an import value of USD 133.38 million. Then it has slightly decreased in 2019 and 2020.

Generally, the import price of avocado has been declining from USD 3,337.31 per ton in 2017 to USD 2,689.67 in 2020.

According to CRI, China’s imported avocados are mainly from Chile, Mexico and Peru. The prices of avocados from Philippine and New Zealand are relatively high. And most avocados are imported though Shanghai and Guangdong Customs.

Readers may obtain the following information through this report:
– Economic Environment of Avocados Industry in China
– Policies in Imported Avocados in China
– Analysis of Supply and Demand of Avocados in China
– Analysis of Imported Avocados in China
– Analysis of Major Sources of Avocados in China
– Price Trend of Imported Avocados in China
– China’s import of avocados into customs

Research Report on China’s Edible Oil Import, 2021-2030

Research Report on China’s LNG (liquefied natural gas) Import, 2021-2025

Research Report on Coal Import in China, 2021-2025

Research Report on Hazelnut Imports in China 2020-2024

Research Report on Coffee Bean Imports in China 2020-2024

Research Report on Cobalt ores and Concentrates Imports in China 2020-2024

Research Report on Cherry Imports in China 2020-2024

The post Research Report on Avocado Imports in China 2020-2024 first appeared on CRI Report.

Research Report on Cherry Imports in China 2020-2024

admin — Wed, 02 Sep 2020 02:55:49 +0000

Description
According to CRI, in 2019, production of domestic cherries was 1.13 million tons in China, while the import volume of cherries were 193.59 thousand tons, which means 14.68% import dependence.
From 2017 to 2019, the total import amount increased from USD 771.26 million to USD 1.40 billion.
Although affected by the COVID-19 in early 2020, the import volume of cherries was still on the rise, increasing by 28.37% compared to the same period in 2019. In the first five months alone, total imports amounted to USD 1.20 billion.
According to CRI, imported fresh cherries were classified to European sour cherries and other cherries in China. Only a small amount of cherries was imported from Canada in 2017 and then stopped.
In recent years, most imported cherries into China are other cherries.
According to CRI, Chile is a big cherry producing country and always the first source of cherries imported to China.
Imported cherries in China were mainly from Chile, the USA and Canada previously. However, China Customs adjusted the quality standards for imported cherries so products from Turkey, Uzbekistan and Kyrgyzstan have also entered the Chinese market rapidly, which means the competition is fiercer.
According to CRI, it is estimated that the import volume of cherries in 2020 would exceed 300 thousand tons. By 2024, the import volume would exceed 430 thousand tons, with a market value of about USD 3.05 billion.

Readers may obtain the following information through this report:
– Economic Environment of Cherries Industry in China
– Policies in Imported Cherries in China
– Analysis of Supply and Demand of Cherries in China
– Analysis of Imported Cherries in China
– Analysis of Major Sources of Cherries in China
– Price Trend of Imported Cherries in China
– China’s import of cherries into customs
-Forecast on China’s imported cherries

The post Research Report on Cherry Imports in China 2020-2024 first appeared on CRI Report.

Research Report on Cobalt ores and Concentrates Imports in China 2020-2024

admin — Wed, 02 Sep 2020 02:55:49 +0000

Cobalt ores and Concentrates Imports in China

2021 Report: Investigation Report on the Chinese Cobalt Market 2021-2025

中文: https://www.yuanzhezixun.com/2021-2025nianquanqiujizhongguoguxingyeyanjiubaogao/

According to CRI, there are only a few cobalt resources in China, the total reserve of cobalt ores in China is 470 kilotons, so it heavily depends on imports.

According to CRI, China’s cobalt ores and concentrates imports increased from 100.99 kilotons in 2017 to 136.10 kilotons in 2018, and then decreased to 90.89 tons in 2019, with a large fluctuation.

In the first half of 2020, the import volume is only 26.81 tons in China, less than one third of that in the whole year of 2019 due to the COVID-19.
Cobalt minerals occur in concentrations high enough to support economic extraction in several diverse settings, all of which display very different examples of mineralization. The most common groups of minerals are sulphides, sulfosalts, arsenides and oxides.

It shows oligopoly in terms of cobalt resources. The market share of the three top companies was up to 40%. The global upstream cobalt resources are mainly controlled by multinational mining enterprises such as Glencore, Molybdenum and Eurasian Resources.

According to CRI, the world’s cobalt resources are rich, but cobalt resource concentration is high, mainly distributed in the Democratic Republic of Congo (the DRC) and Australia. The DRC is always the biggest source of China’s cobalt imports.

Readers may obtain the following information through this report:
– Economic Environment of Cobalt ores and concentrates Industry in China
– Policies in Imported Cobalt ores and concentrates in China
– Analysis of Supply and Demand of Cobalt ores and concentrates in China
– Analysis of Imported Cobalt ores and concentrates in China
– Analysis of Major Sources of Cobalt ores and concentrates in China
– Price Trend of Imported Cobalt ores and concentrates in China
– China’s import of cobalt ores and concentrates into customs

The post Research Report on Cobalt ores and Concentrates Imports in China 2020-2024 first appeared on CRI Report.

Research Report on China Wig Export 2020-2024

admin — Wed, 15 Jul 2020 01:51:42 +0000

Description
Materials of wigs include human hair, chemical fiber, high-temperature protein silk and animal hair, etc. Among them, human hair wigs are the best, and most expensive.
The exported wig products from China can be divided into four types: raw material of wigs, human hair wigs, chemical fiber wigs, and other material wigs.
China’s wig export accounts for more than 70% of the global supply.
According to CRI, in 2019, China exported 67.08 thousand tons wig products, valued USD 3.59 billion, with average price USD 53.56 per kilogram.
Affected by the COVID-19, the export volume of wigs has decreased in the first five months of 2020, but the price kept rising, especially raw materials of wigs.
The world’s largest consumer market of wigs is North America, which accounts for 62% of the global share. Africa is another main market of wig consumption, since African women needs lots of wigs. At present, South America is also becoming an important market of wigs.
According to CRI, the major departures of China’s wig export are Henan, Shandong and Zhejiang. Especially Henan Province has the most developed wig industry.

Readers may obtain the following information through this report:
– Economic Environment of Wigs Industry in China
– Policies in Exported Wigs in China
– Analysis on Supply of Wigs in China
– Analysis of Exported Wigs in China
– Analysis of Major Destinations of Exported Wigs in China
– Price Trend of Exported Wigs in China

Organic Personal Care Products Market: Market Segments: By Product (Skin Care, Hair Care, Oral Care, Cosmetics and Others); By Distribution Channel (Hypermarket/Supermarkets, Specialist Retail Stores, Online Retail Stores and Others); and Region – Global Analysis by Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030

The post Research Report on China Wig Export 2020-2024 first appeared on CRI Report.

Research Report on China Tire Export 2020-2024

admin — Wed, 15 Jul 2020 01:51:41 +0000

Description
China’s annual production of pneumatic tires was more than 800 million in 2015-2019, the highest output was 1.04 billion in 2018. Due to the upstream rubber industry and the downstream automobile industry, the tire production in 2019 has declined, only 842.26 million.
According to CRI, the tires exported by China are new pneumatic tires, which are mainly used for passenger cars and commercial vehicles (buses and lorries).
According to CRI, from 2017 to 2019, the export volume increased from 289.59 million to 315.58 million. Affected by the COVID-19 from January to April 2020, the number of tire exports is relatively small, only 84.71 million, down by 13.45 million, or 13.70% compared to the same period in 2019.
Although the volume of passenger car tires exports is more than that of commercial car tires, the amount of commercial car tires exports is higher. In 2019, the export volume of passenger car tires was 223.23 million, the value was USD 5,569.82 million, while the volume of commercial vehicle tires was 92.36 million, worth USD 7,350.04 million.
The export destinations of passenger car tires are always relatively scattered, with only the UK keeping ranking the first, accounting for 8-10% of the total volume. While commercial vehicle tires were mainly exported to the United States. Even in the face of the Sino-U.S. trade war and epidemic situation, the United States was still the first export destination, accounting for 14-26% of the total volume.
China government encourages enterprises to export tires, while lots of other countries have raised tariffs on Chinese tires. Considering pandemic and other factors, the export is estimated to be relatively low in 2020 and gradually recovered after 2021.
According to CRI, the USA, the UK and Mexico are expected to be the top three export destinations in next five years, followed by Germany, Saudi Arabia and the United Arab Emirates.

Readers may obtain the following information through this report:
– Economic Environment of Tires Industry in China
– Policies in Exported Tires in China
– Analysis on Supply of Tires in China
– Analysis of Exported Tires in China
– Analysis of Major Destinations of Exported Tires in China
– Price Trend of Exported Tires in China
– Driving Forces and Opportunities of Exported Tires in China
– Forecast on Exported Tires in China 2020-2024

The post Research Report on China Tire Export 2020-2024 first appeared on CRI Report.

Research Report on China Mobile Phone Export 2020-2024

admin — Wed, 15 Jul 2020 01:51:39 +0000

Description
According to CRI, from 2017 to 2019, the total volume of China’s mobile phone exports declined from 1,213.22 million to 994.09 million. Although the total export volume showed a trend of decreasing, the export value in 2018 increased by 11.52% compared to 2017, reaching USD 140.64 billion. China’s mobile phone export price was also at the highest level in 2018, increased by 20.92% year on year, due to the rapid development of domestic high-end smart phones and the rising cost of core parts.
2018 is a year of strong rise of domestic smart phones, especially high-end ones. The competitiveness of domestic medium and high-end smart phones represented by Huawei mobile phones has been enhanced, and even penetrated the price band exclusive to Apple mobile phones.
Hong Kong is always the biggest market among China’s mobile phone export destinations.
According to CRI, more than half of China’s mobile phone exports came from Guangdong Province. Huaqiangbei, located in Shenzhen, Guangdong Province, is the most prosperous commercial street in Shenzhen, also the main hub of domestic electronic products circulation, especially famous for its mobile phone wholesale and retail business.
China’s government encourages enterprises to export mobile phones, with export tax rebate rate 13%, while the USA levied additional duty on Chinese mobile phones.

Readers may obtain the following information through this report:
– Economic Environment of Mobile Phone Industry in China
– Policies in Exported Mobile Phone in China
– Analysis on Supply of Mobile Phone in China
– Analysis of Exported Mobile Phone in China
– Analysis of Major Destinations of Exported Mobile Phone in China
– Price Trend of Exported Mobile Phone in China

The post Research Report on China Mobile Phone Export 2020-2024 first appeared on CRI Report.

Market Research Report on Aceglutamide in China, 2010-2019

admin — Fri, 17 Aug 2018 09:05:23 +0000

Description
Aceglutamide refers to acetyl compounds of glutamine, which is capable to improve metabolism of nerve cell and to maintain nerve-stress and lower blood amine. It can also apply to traumatic brain injury coma, hepatic coma, hemiplegia, paraplegia, polio sequelae, sequelae of traumatic brain injury, mental deterioration, nervous headache and low back pain through Blood Brain Barrier(BBB).
According to CRI investigation on market, the market of Aceglutamide in China shows a fluctuated trend from 2005 to 2011. The annual sales value of hospitals fluctuated around CNY 30 million. From 2011 to 2014, the market scale of Aceglutamide in China was increasing expanding, with sales CAGR of about 23.2%. Since 2014, its sales volume has exceeded CNY 40 million.
In next few years, it is predicted that the demand for central stimulant drugs in Chinese market will continue to increase, which will promote the market size of Aceglutamide.

Through this report, readers can learn the followings and more:
– the market size of Aceglutamide in China
– the market competition pattern of Aceglutamide in China
– the sales price of Aceglutamide produced by different enterprises in China
– the outlook on Aceglutamide market in China

The author recommends the following people to purchase this report:
– Central stimulant drug manufacturing enterprise
– Investors / research institutes focusing on Chinese drug market
– If interested in Chinese pharmaceutical market, you can contact CRI for customized survey service.

Table of Contents
1 Related Concept of Aceglutamide
1.1 Indications
1.2 Sales Status of Global Market

2 Market Overview of Aceglutamide in China
2.1 The Patent Status and Approval Information of Aceglutamide in China
2.2 The Main Producers
2.3 Market Size

3 Inquiry on The Sales Status of Aceglutamide in China
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Region
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Region

4 Inquiry on the Market Share of Chinese major Aceglutamide Producers
4.1 Market Share of Producing Businesses by Sales Value
4.2 Market Share of Producing Businesses by Sales Volume

5 Research on the Dosage of Aceglutamide in China
5.1 Dosage Share by Sales Value
5.2 Dosage Share by Sales Volume

6 The Reference Price of Aceglutamide in Chinese Hospitals
6.1 Hunan CommScope Pharmaceutical Co., Ltd.
6.2 Wuhan Pusheng Pharmaceutical Co., Ltd.
6.3 Hunan Wuzhoutong Pharmaceutical Co., Ltd.
6.4 Shenyang Xinma Pharmaceutical Co., Ltd.
6.5 Haikou Qili Pharmaceutical Co., Ltd.

7 The Main Producers of Aceglutamide in the Chinese Market, 2010-2014
7.1 Hunan CommScope Pharmaceutical Co., Ltd.
7.2 Wuhan Pusheng Pharmaceutical Co., Ltd.
7.3 Hunan Wuzhoutong Pharmaceutical Co., Ltd.
7.4 Shenyang Xinma Pharmaceutical Co., Ltd.
7.5 Haikou Qili Pharmaceutical Co., Ltd.

8 Market Outlook of Aceglutamide in China, 2015-2019
8.1Prediction of Market size
8.2 Prediction of Competition Pattern

Part of the Table of Contents
Chart The Patent Status of Aceglutamide in China
Chart The Approval Information of Aceglutamide in China
Chart The Sales Value of Aceglutamide in China, 2010- 2014
Chart The Sales Value of Aceglutamide in Parts of China, 2010-2014
Chart The Sales Volume of Aceglutamide in China, 2010-2014
Chart The Sales Volume of Aceglutamide in Parts of China, 2010-2014
Chart The Market Share of Top 5 Sales Value of Aceglutamide of Enterprises in China, 2010-2014
Chart The Sales Value and The Market Share of Aceglutamide produced by Hunan Commscope Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Value and The Market Share of Aceglutamide produced by Wuhan Pusheng Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Value and The Market Share of Aceglutamide produced by Hunan Wuzhoutong Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Value and The Market Share of Aceglutamide produced by Shenyang Xinmali Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Value and The Market Share of Aceglutamide produced by Haikou Qili Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Market Share of Top 5 Sales Volume of Aceglutamide of Enterprises in China, 2010-2014
Chart The Sales Volume and The Market Share of Aceglutamide produced by Hunan Wuzhoutong Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Volume and The Market Share of Aceglutamide produced by Hunan Commscope Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Volume and The Market Share of Aceglutamide produced by Haikou Qili Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Value and The Market Share of Aceglutamide produced by Chengdu Wutaishan Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Value and The Market Share of Aceglutamide produced by Wuhan Pusheng Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Price of Aceglutamide produced by Hunan Commscope Pharmaceutical Co., Ltd in some cities of China in 2004
Chart The Sales Price of Aceglutamide produced by Wuhan Pusheng Pharmaceutical Co., Ltd in some cities of China in 2004
Chart The Sales Price of Aceglutamide produced by Hunan Wuzhoutong Pharmaceutical Co., Ltd in some cities of China in 2004
Chart The Sales Price of Aceglutamide produced by Shenyang Xinma Pharmaceutical Co., Ltd in some cities of China in 2004
Chart The Sales Price of Aceglutamide produced by Haikou Qili Pharmaceutical Co., Ltd in some cities of China in 2004

The post Market Research Report on Aceglutamide in China, 2010-2019 first appeared on CRI Report.

Market Research Report on Polyresistin in China, 2010-2019

admin — Fri, 17 Aug 2018 09:05:23 +0000

Description
Polyresistin refers to a kind of polysaccharides extracted from hemolytic streptococcus through fermenting. Polyresistin is a system of enhancing immune, which can inhibit the growth and metabolism of tumor cells, promote the growth of erythropoietin and enhance the reticuloendothelial system, activation of lymphocytes, which can strengthen and regulate immune function. It can also improve the body’s stress function and enhance the body’s non-specific resistance and have the function of anti-radiation damage, which can enhance the effect of radiation oncology.
Polyresistin primarily for the treatment of leukopenia, aplastic anemia; prevention of immune dysfunction caused by a variety of infections; with various types of cancer, radiotherapy, chemotherapy or adjuvant treatment after surgery, radiation injury prevention; at the same time with this product in infection allergic arthritis, recurrent respiratory infections, treatment of peptic ulcer, chronic atrophic gastritis, cervical erosion, oral mucosal disease and the like.
In recent years, Polyresistin keeps good sales in the Chinese market. According to the CRI’s investigation on sample hospitals, the sales value of Polyresistin increased to CNY 250 million in 2014 from less than CNY 70 million in 2016, with CAGR of 17.7%.
With the aggravation of environmental pollution in China, as well as lifestyle changes brought about by economic development, China is expected to have an increasing incidence of cancer, respiratory tract infections in the future, which will facilitate enlarging the market size of Polyresistin.

Through this report, readers can learn the followings and more:
– the market size of Polyresistin in China
– the market competition pattern of Polyresistin in China
– the sales price of Polyresistin produced by different enterprises in China
– the outlook on Polyresistin market in China

The author recommends the following people to purchase this report:
– immunomodulator manufacturing enterprise
– Investors / research institutes focusing on Chinese drug market
– If interested in Chinese pharmaceutical market, you can contact CRI for customized survey service.

Table of Contents
1 Related Concept of Polyresistin
1.1Indications
1.2 Sales Status of Global Market

2 Market Overview of Polyresistin in China
2.1 The Patent Status and Approval Information of Polyresistin in China
2.2 The Main Producers
2.3 Market Size

3 Inquiry on The Sales Status of Polyresistin in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Region
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Region

4 Inquiry on the Market Share of Chinese major Polyresistin Producers, 2010-2014
4.1 Market Share of Producing Businesses by Sales Value
4.2 Market Share of Producing Businesses by Sales Volume

5 Research on the Dosage of Polyresistin in China, 2010-2014
5.1 Dosage Share by Sales Value
5.2 Dosage Share by Sales Volume

6 The Reference Price of Polyresistin in Chinese Hospitals in 2014
6.1 Sinopharm A-Think Pharmaceutical Co., Ltd.
6.2 Chengdu Li’er Pharmaceutical Co., Ltd.
6.3 Sichuan Aobang Pharmaceutical Co., Ltd.
6.4 Guangdong Winnerway Pharmaceutical Co., Ltd.
6.5 Pearl Ocean Pharmaceutical Holdings, Ltd.

7 The Main Producers of Polyresistin in the Chinese Market, 2010-2014
7.1 Sinopham A-Think Pharmaceutical Co., Ltd.
7.2 Chengdu Li’er Pharmaceutical Co., Ltd.
7.3 Sichuan Aobang Pharmaceutical Co., Ltd.
7.4 Guangdong Winnerway Pharmaceutical Co., Ltd.
7.5 Pearl Ocean Pharmaceutical Holdings, Ltd.

8 Market Outlook of Polyresistin in China, 2015-2019
8.1Prediction of Market size
8.2 Prediction of Competition Pattern

Part of the Table of Contents
Chart The Approval Information of Polyresistin in China
Chart The Sales Value of Polyresistin in China, 2010- 2014
Chart The Sales Value of Polyresistin in Parts of China, 2010-2014
Chart The Sales Volume of Aceglutamide in China, 2010-2014
Chart The Sales Volume of Polyresistin in Parts of China, 2010-2014
Chart The Market Share of Top 5 Sales Value of Polyresistin of Enterprises in China, 2010-2014
Chart The Sales Value and The Market Share of Polyresistin produced by Sinopharm A-Think Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Value and The Market Share of Polyresistin produced by Chengdu Li’er Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Value and The Market Share of Polyresistin produced by Guangdong Winnerway Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Value and The Market Share of Polyresistin produced by Qingdao Baiyang Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Value and The Market Share of Polyresistin produced by other corporations, 2010-2014
Chart The Market Share of Top 5 Sales Volume of Polyresistin of Enterprises in China, 2010-2014
Chart The Sales Volume and The Market Share of Polyresistin produced by Chengdu Li’er Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Volume and The Market Share of Polyresistin produced by Sinopharm A-Think Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Volume and The Market Share of Polyresistin produced by Sichuan Aobang Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Value and The Market Share of Polyresistin produced by Guangdong Winnerway Pharmaceutical Co., Ltd in China, 2010-2014
Chart The Sales Price of Polyresistin produced by Sinopharm A-Think Pharmaceutical Co., Ltd in some cities of China in 2004
Chart The Sales Price of Polyresistin produced by Chengdu Li’er Pharmaceutical Co., Ltd in some cities of China in 2004
Chart The Sales Price of Polyresistin produced by Sichuan Aobang Pharmaceutical Co., Ltd in some cities of China in 2004
Chart The Sales Price of Polyresistin produced by Guangdong Winnerway Pharmaceutical Co., Ltd in some cities of China in 2004
Chart The Sales Price of Polyresistin produced by Qingdao Baiyang Pharmaceutical Co., Ltd in some cities of China in 2004

The post Market Research Report on Polyresistin in China, 2010-2019 first appeared on CRI Report.

Investigation Report on China Fluoxetine Market, 2010-2019

admin — Fri, 17 Aug 2018 09:04:45 +0000

Description
WHO predicts that by 2020, depression will probably become the second largest disease next to cardio-cerebrovascular disease. Every year, the suicide death toll of depression around the world is up to 1 million people and the amount of depression patients in China has reached 90 million. At present, the recognition rate of depression in our country is only 30% and the identified patients seeking medical advice is also 30%, which means less than 10% of the depressive patients were likely to utilize medical service. Clinical experience shows that 80% of the patients can achieve clinical cure, if having standard treatment, expect very few patients with refractory type, others will be improvement.
Original antidepressants Fluoxetine produced by Eli Lilly and Company was approved for the treatment of depression first in Belgium in 1986.
Fluoxetine is a kind of selective serotonin reuptake inhibitors (SSRI) antidepressants and its medicinal form is Fluoxetine hydrochloride. Eli Lilly and Company named their products “the optimal solution” (Prozac) which is used for the treatment of adult depression, obsessive-compulsive disorder and neurological bulimia in clinical practice as well as panic disorder with or without agoraphobe. At the end of 1987, Fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to enter American market, and it entered the Chinese market on March 30, 1995. Eli Lilly and Company’s patent for Prozac expired in August of 2001, since then there have appeared a large number of Fluoxetine drugs on the market.
There is a broad demand market of Fluoxetine in China. From 2010 to 2014, according to CRI’s survey on sample hospitals, CAGR of Fluoxetine is up to 9.68%. Eli Lilly and Company (Spain), Eli Lilly and Company (Britain), Patheon (FR), Shanghai Zhongxi Pharmaceutical Co., Ltd, Changzhou Siyao Pharmaceutical Co., Ltd, SCCPC, WATSON Pharmaceuticals (Changzhou) Co., Ltd and Shanxi C&Y Pharmaceutical Group Co., Ltd. occupy large portion in the sales market. Measured by sales value, Lilly (Spain) enjoyed the highest market share, which reached 75% in 2014.
In China, with many people bearing a proliferation of pressure from life, learning and work, the amount of depressive patients will also present an increasing tendency. In conclusion, there exists huge potential in Chinese market demand for Fluoxetine.

Table of Contents
1 Related Concepts of Fluoxetine
1.1 Indication
1.2 Sales Situation of Global Market

2 Market Profile of Fluoxetine in China
2.1 Patent and Approval Information of Fluoxetine in China
2.2 Major Manufacturers
2.3 Market Scale

3 Survey on Fluoxetine Sales Situation in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Fluoxetine Manufacturers in China, 2010-2014
4.1 Market Share of Manufacturers by Sales Value
4.2 Market Share of Manufacturers by Sales Volume

5 Survey on Dosage Forms of Fluoxetine in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Sales Price of Fluoxetine in Chinese Hospitals in 2014
6.1 Patheon France (FR)
6.2 Shanghai Zhongxi Pharmaceutical Co., Ltd.
6.3 Shanxi C&Y Pharmaceutical Group Co., Ltd.
6.4 WATSON Pharmaceuticals (Changzhou) Co., Ltd.
6.5 Changzhou Siyao Pharmaceutical Co., Ltd.
6.6 Suzhou Chung-Hwa Pharmaceutical & Chemical Industrial Co., Ltd. (SCCPC)
6.7 Eli Lilly and Company (Britain)
6.8 Eli Lilly and Company (Spain)

7 Major Production Enterprises of Fluoxetine in Chinese Market, 2010-2014
7.1 Patheon France (FR)
7.2 Shanghai Zhongxi Pharmaceutical Co., Ltd.
7.3 Shanxi C&Y Pharmaceutical Group Co., Ltd.
7.4 WATSON Pharmaceuticals (Changzhou) Co., Ltd.
7.5 Changzhou Siyao Pharmaceutical Co., Ltd.
7.6 Suzhou Chung-Hwa Pharmaceutical & Chemical Industrial Co., Ltd. (SCCPC)
7.7 Eli Lilly and Company

8 Market Prospect of Fluoxetine in China, 2015-2019
8.1 Prediction of Market Scale
8.2 Prediction of Competition Pattern

Table of Selected Charts
Chart Patent Status of Fluoxetine in China
Chart Approval Information of Fluoxetine in China
Chart Sales Situation of Fluoxetine in China
Chart Sales Value of Fluoxetine in China, 2010-2014
Chart Sales Value of Fluoxetine in Some Regions of China, 2010-2014
Chart Sales Volume of Fluoxetine in China, 2010-2014
Chart Market Share of Corporations of TOP5 Fluoxetine Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Fluoxetine Produced by Eli Lilly and Company (Spain), 2010-2014
Chart Sales Value and Market Share of Fluoxetine Produced by Eli Lilly and Company (Britain), 2010-2014
Chart Sales Value and Market Share of Fluoxetine Produced by Patheon (FR) in China, 2010-2014
Chart Sales Value and Market Share of Fluoxetine Produced by Shanghai Zhongxi in China, 2010-2014
Chart Sales Value and Market Share of Fluoxetine Produced by Changzhou Siyao, 2010-2014
Chart Sales Value and Market Share of Fluoxetine Produced by other manufacturers in China, 2010-2014
Chart Sales Value and Market Share of Fluoxetine Tablet in China, 2010-2014
Chart Sales Value and Market Share of Fluoxetine Capsule in China, 2010-2014
Chart Sales Price of Fluoxetine Produced by Patheon France (FR) in Some Chinese Cities in 2014
Chart Sales Price of Fluoxetine Produced by Shanghai Zhongxi Pharmaceutical Co., Ltd. in Some Chinese Cities in 2014
Chart Sales Price of Fluoxetine Produced by Shanxi C&Y Pharmaceutical Group Co., Ltd. in Some Chinese Cities in 2014
Chart Sales Price of Fluoxetine Produced by WATSON Pharmaceuticals (Changzhou) Co., Ltd. in Some Chinese Cities in 2014
Chart Sales Price of Fluoxetine Produced by Changzhou Siyao Pharmaceutical Co., Ltd. in Some Chinese Cities in 2014
Chart Sales Price of Fluoxetine Produced by Suzhou Chung-Hwa Pharmaceutical & Chemical Industrial Co., Ltd. (SCCPC)in Some Chinese Cities in 2014
Chart Sales Price of Fluoxetine Produced by Eli Lilly and Company in Some Chinese Cities in 2014

The post Investigation Report on China Fluoxetine Market, 2010-2019 first appeared on CRI Report.

Investigation Report on China Methylcobalamin Market, 2010-2019

admin — Fri, 17 Aug 2018 09:04:45 +0000

Description
Peripheral neuropathy is a syndrome, which is a single or any combination form of sensory loss, muscle weakness and atrophy, decreased tendon reflex and vasomotion symptoms. The factors which lead to peripheral neuropathy are that the damage of single neural limitation is a common cause of trauma, while multiple single neuropathy occurs secondary to collagen vascular disease; Multiple neuropathy may be caused by toxins, toxic substances, nutrition deficiency, metabolic disease and malignant tumors.
Methylcobalamin, derivative of Vitamin B12, is active Vitamin B12 and the therapeutic drug of peripheral neuropathy. It can promote intraneural nucleic acid, protein and metabolism, facilitate the synthesis of DNA,RNA as well as the synthesis of lecithin lipid, which is the main component of myelin sheath, and accelerate to restore the damaged nerve tissue to improve the transformation of nerve tissue and the disturbance of metabolism. In addition, it also works on restraining unusual exciting conduction of nerve tissue.

Methylcobalamin,. whose trade name is mecobalamin, was developed by Eisai Co., Ltd. and put in the market in Japan in the middle of 1980s.In 1996, mecobalamin entered the Chinese market.
Methylcobalamin developed rapidly after entering China. Its annual sales value increased from less than 200 million CNY in 2005 to 441 million CNY in 2014, with CAGR of 12.32%. It had broad market demand in China. Eisai (Suzhou) Pharmaceutical Co., Ltd, Eisai Co., Ltd. (Japan), Jiangsu Sihuan Bioengineering Co., Ltd, Nanjing Hailing Pharmaceutical Co., Ltd. and NCPC occupy large market share, among which Eisai (Suzhou) Pharmaceutical Co., Ltd occupies most, whose annual market share of sales value was over 40% in 2014.
It is predicted that in next few years, the incidence of peripheral neuropathy in China will gradually rise, making the market scale of methylcobalamin continue to increase.

Through this report, readers can get the followings and more information:
-Market scale of Methylcobalamin in China
-Market Competitive pattern of Methylcobalamin in China
-Sales price of Methylcobalamin made by different enterprises in China
-Market outlook of Methylcobalamin in China

The author recommends the following people to purchase this report:
– Production enterprises of methylcobalamin drugs
-Investors/research institutions focusing on Chinese pharmaceutical market
–If interested in Chinese pharmaceutical market, you can contact CRI for customized survey service.

Table of Contents
1 Related Concepts of Methylcobalamin
1.1 Indications
1.2 Sales Status in Global Market

2 Market Profile of Methylcobalamin in China
2.1 Patent and Approval Information of Methylcobalamin in China
2.2 Major Manufacturing Enterprises
2.3 Market Scale

3 Survey on Methylcobalamin Sales in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Methylcobalamin Production Enterprises in China, 2010-2014
4.1 Market Share of Producing Businesses by Sales Value
4.2 Market Share of Producing Businesses by Sales Volume

5 Survey on Dosage Forms of Methylcobalamin in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Sales Price of Methylcobalamin in Chinese Hospitals in 2014
6.1 North China Pharmaceutical Group Corp. (NCPC)
6.2 Eisai (Suzhou) Pharmaceutical Co., Ltd.
6.3 Eisai Co., Ltd. (Japan)
6.4 Nanjing Hailing Pharmaceutical Co., Ltd.
6.5 Jiangsu Sihuan Bioengineering Co., Ltd.

7 Major Production Enterprises of Methylcobalamin in Chinese Market, 2010-2014
7.1 North China Pharmaceutical Group Corp. (NCPC)
7.2 Eisai (Suzhou) Pharmaceutical Co., Ltd.
7.3 Eisai Co., Ltd. (Japan)
7.4 Nanjing Hailing Pharmaceutical Co., Ltd.
7.5 Jiangsu Sihuan Bioengineering Co., Ltd.

8 Market Outlook of Methylcobalamin in China, 2015-2019
8.1 Prediction of Market Size
8.2 Prediction of Competitive Pattern
Selected Charts
Chart Patent Status of Methylcobalamin in China
Chart Approval Information of Methylcobalamin in China
Chart Sales Status of Methylcobalamin in China
Chart Sales Value of Methylcobalamin in China, 2010-2014
Chart Sales Value of Methylcobalamin in Some Regions of China, 2010-2014
Chart Sales Volume of Methylcobalamin in China, 2010-2014
Chart Sales Volume of Methylcobalamin in Some Regions of China, 2010-2014
Market Share of Corporations of TOP5 Methylcobalamin Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Methylcobalamin Produced by Eisai (Suzhou) in China, 2010-2014
Chart Sales Value and Market Share of Methylcobalamin Produced by Eisai (Japan) in China, 2010-2014
Chart Sales Value and Market Share of Methylcobalamin Produced by Jiangsu Sihuan in China, 2010-2014
Chart Sales Value and Market Share of Methylcobalamin Produced by Nanjing Hailing in China, 2010-2014
Chart Sales Value and Market Share of Methylcobalamin Produced by NCPC in China, 2010-2014
Chart Sales Value and Market Share of Methylcobalamin Injection in China, 2010-2014
Chart Sales Value and Market Share of Methylcobalamin Tablet in China, 2010-2014
Chart Sales Value and Market Share of Methylcobalamin Capsule in China, 2010-2014
Chart Sales Price of Methylcobalamin Produced by NCPC in Some Chinese Cities in 2014
Chart Sales Price of Methylcobalamin Produced by Eisai (Suzhou) in Some Chinese Cities in 2014
Chart Sales Price of Methylcobalamin Produced by Eisai (Japan) in Some Chinese Cities in 2014
Chart Sales Price of Methylcobalamin Produced by Nanjing Hailing Pharmaceutical Co., Ltd. in Some Chinese Cities in 2014
Chart Sales Price of Methylcobalamin Produced by Jiangsu Sihuan Bioengineering Co., Ltd. in Some Chinese Cities in 2014

The post Investigation Report on China Methylcobalamin Market, 2010-2019 first appeared on CRI Report.